Skip to main content
TipRanks
Go Ultimate75% OFF

Biomea Fusion (BMEA) AI Stock Analysis

1,215 Followers
BMEA

Biomea Fusion

(NASDAQ:BMEA)

Select Model
Rating:45Neutral
Price Target:$0.51▼(-13.78% Downside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial fundamentals (pre-revenue, persistent losses, ongoing cash burn, and sharply reduced equity) and bearish technicals (price below all key moving averages and negative MACD). A positive offset comes from improving loss/cash burn trajectory and a constructive Phase 1 update for BMF-650, but these are not enough to outweigh current funding and trend risks.

Positive Factors
BMF-650 Phase 1 ProgressThe Phase 1 readout advances BMF-650 into human clinical development and supports continued assessment of its oral GLP-1 approach. Its stated focus on tolerability, one-step titration and bioavailability could provide durable product differentiation if later trials confirm these benefits.
Negative Factors
Pre-Revenue Business ModelThe absence of product revenue means Biomea currently lacks commercial operating leverage and must fund research and development before establishing a recurring revenue base. This leaves future financial performance highly dependent on clinical progress and eventual product commercialization.

Biomea Fusion (BMEA) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%100%125%BMEA-41.78%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$38.52M
Dividend Yield
―
Average Volume (3M)
2.21M
Price to Earnings (P/E)
-1.9
Beta (1Y)
2.02
Revenue Growth
―
EPS Growth
87.11%
Country
US
Employees
41
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Biomea Fusion Business Overview & Revenue Model

Company Description

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALE...

Biomea Fusion Financial Statement Overview

Summary

Pre-revenue with ongoing losses and negative free cash flow, keeping financing risk elevated. Positives include a meaningful improvement in net loss and cash burn versus prior years and low leverage, but equity has fallen sharply over time, reducing balance-sheet cushion.

Income Statement

12Very Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-93.00K-1.41M0000
EBITDA-22.19M-60.39M-136.68M-115.74M-81.14M-41.32M
Net Income-22.31M-61.80M-138.43M-117.25M-81.83M-41.57M
Balance Sheet
Total Assets28.10M58.57M79.94M199.93M129.31M185.71M
Cash, Cash Equivalents and Short-Term Investments26.40M55.81M58.28M176.87M113.05M173.52M
Total Debt506.00K1.59M8.77M10.30M2.29M2.85M
Total Liabilities20.51M29.02M28.36M30.69M20.77M6.92M
Stockholders Equity7.59M29.55M51.57M169.24M108.54M178.78M
Cash Flow
Free Cash Flow-43.32M-70.37M-120.26M-99.96M-63.45M-38.61M
Operating Cash Flow-43.32M-70.37M-119.89M-96.59M-62.42M-35.44M
Investing Cash Flow550.00K0-362.00K-2.22M27.34M-33.35M
Financing Cash Flow22.53M67.90M1.67M163.80M1.24M153.19M

Biomea Fusion Technical Analysis

Technical Analysis SentimentNegative
Last Price0.59

Price Trends

50DMA1.03Negative
100DMA1.23Negative
200DMA1.32Negative

Market Momentum

MACD-0.12Negative
RSI39.71Neutral
STOCH47.36Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Negative. The current price of 0.59 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 1.03, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 39.71 is Neutral, neither overbought nor oversold. The STOCH value of 47.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMEA.

Biomea Fusion Risk Analysis

Biomea Fusion disclosed 91 risk factors in its most recent earnings report. Biomea Fusion reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.We may seek approval of our product candidate into RTOR. This program may not lead to a faster regulatory review or approval process and does not increase the likelihood that our product candidate(s) will receive marketing approval.Q4, 2023

Biomea Fusion Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BMEA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AGENAGEN57Neutral$277.81M8.35-15.48%―25.38%―
INOINO55Neutral$320.29M-2.15-9999.00%―63.93%68.94%
OVIDOVID52Neutral$441.63M-13.29-23.38%―-78.05%63.85%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BMEABMEA45Neutral$42.76M-1.86-131.27%――87.11%
ATOSATOS42Neutral$17.46M-0.45-117.07%――-10.80%
SEERSEER40Underperform$77.30M-1.20-27.03%―-14.56%16.31%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%BMEAAGENINOATOSOVIDSEERDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BMEA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BMEABiomea Fusion Inc0.59-0.39-40.00%
AGENAgenus Inc.6.141.9245.50%
INOInovio Pharmaceuticals1.71-0.05-2.84%
ATOSAtossa Therapeutics, Inc.1.75-9.95-85.05%
OVIDOvid Therapeutics2.340.9467.14%
SEERSeer, Inc.1.39-0.58-29.70%

Biomea Fusion Corporate Events

Business Operations and StrategyProduct-Related Announcements

Biomea Fusion Reports Phase 1 Results for BMF-650

Positive
Oct 14, 2026

On October 13, 2026, Biomea Fusion hosted a conference call and webcast to present topline results from its ongoing Phase 1 GLP-131 clinical trial of BMF-650 in otherwise healthy overweight or obese adults. The company simultaneously released a press...

Business Operations and StrategyProduct-Related Announcements

Biomea Fusion Updates Timeline for BMF-650 Phase I Data

Neutral
Sep 22, 2026

On September 22, 2026, Biomea Fusion, Inc. reported an updated timeline for topline results from its ongoing Phase I GLP-131 clinical trial of BMF-650, conducted in obese but otherwise healthy volunteers. The company now expects to release these init...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026